$127.12
1.48% yesterday
Nasdaq, Nov 25, 10:00 pm CET
ISIN
US3755581036
Symbol
GILD

Gilead Sciences Stock price

$127.12
+6.65 5.52% 1M
+19.75 18.39% 6M
+34.75 37.62% YTD
+36.63 40.48% 1Y
+40.86 47.37% 3Y
+67.62 113.65% 5Y
+19.34 17.94% 10Y
+113.56 837.64% 20Y
Nasdaq, Closing price Tue, Nov 25 2025
+1.85 1.48%
ISIN
US3755581036
Symbol
GILD
Industry

New AI Insights on Gilead Sciences Insights AI Insights on Gilead Sciences

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Key metrics

Basic
Market capitalization
$157.7b
Enterprise Value
$148.4b
Net debt
-
Cash
$9.4b
Shares outstanding
1.2b
Valuation (TTM | estimate)
P/E
19.7 | 15.3
P/S
5.4 | 5.3
EV/Sales
5.1 | 5.0
EV/FCF
15.3
P/B
7.4
Dividends
DPS
$3.16
Yield 1Y | 5Y
2.5% | 3.8%
Growth 1Y | 5Y
2.6% | 3.0%
Payout 1Y | 3Y
810.5% | 105.6%
Increased
11 Years
Financials (TTM | estimate)
Revenue
$29.1b | $29.6b
EBITDA
- | $14.8b
EBIT
$11.3b | $13.5b
Net Income
$8.1b | $10.3b
Free Cash Flow
$9.7b
Growth (TTM | estimate)
Revenue
2.8% | 3.1%
EBITDA
- | 8.8%
EBIT
4.5% | 24.4%
Net Income
6,336.5% | 2,051.6%
Free Cash Flow
2.5%
Margin (TTM | estimate)
Gross
78.7%
EBITDA
- | 49.9%
EBIT
39.0%
Net
27.9% | 34.9%
Free Cash Flow
33.2%
Financial Health
Equity Ratio
32.8%
Return on Equity
2.5%
ROCE
24.5%
ROIC
-
Debt/Equity
-
More
EPS
$6.5
FCF per Share
$7.8
Short interest
1.5%
Employees
18k
Rev per Employee
$1.6m
Show more

Create a Free Account to create an Gilead Sciences alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Gilead Sciences Stock Analysis

Unlock Scores for Free

Analyst Opinions

36 Analysts have issued a Gilead Sciences forecast:

28x Buy
78%
8x Hold
22%

Analyst Opinions

36 Analysts have issued a Gilead Sciences forecast:

Buy
78%
Hold
22%

Financial data from Gilead Sciences

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
29,087 29,087
3% 3%
100%
- Direct Costs 6,191 6,191
1% 1%
21%
22,896 22,896
4% 4%
79%
- Selling and Administrative Expenses 5,793 5,793
2% 2%
20%
- Research and Development Expense 5,771 5,771
5% 5%
20%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT 11,333 11,333
4% 4%
39%
Net Profit 8,110 8,110
6,337% 6,337%
28%

In millions USD.

Don't miss a Thing! We will send you all news about Gilead Sciences directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Gilead Sciences Stock News

Positive
Seeking Alpha
about 19 hours ago
Gilead Sciences remains a bullish pick, with raised guidance and strong Q3/25 results, driving optimism for continued growth. Gilead Sciences key growth drivers, include robust sales from Livdelzi and Yeztugo, alongside patent protection for Biktarvy until 2036. Despite a higher P/FCF ratio, Gilead Sciences is still undervalued, with an intrinsic value estimate of $146.12, supporting its invest...
Neutral
Business Wire
one day ago
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Foundation today announced that it has committed over $3 million in grants to expand access to food in communities across the United States. Gilead Foundation Healing Hunger awards will enable 14 regionally focused organizations to meet the unique needs of their communities by improving long-term nutrition access. The funding, distributed through the...
Positive
Seeking Alpha
5 days ago
Gilead Sciences, Inc. continues to outperform, driven by its dominant HIV division and strong Q3 results that surpassed analyst expectations. GILD's HIV portfolio, led by Biktarvy and new launch Yeztugo, is expected to sustain growth with no major patent expiries until 2036. While oncology / immunology remain weaker segments, recent strategic M&A like CymaBay and a new CMO with oncology experti...
More Gilead Sciences News

Company Profile

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firms primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster, CA.

Head office United States
CEO Daniel O'Day
Employees 17,600
Founded 1987
Website www.gilead.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today